HBR Executive delivers trusted insights and actionable strategies to guide leaders through consequential decisions. Practical tools, and forward-looking perspectives cut through the noise to equip you to navigate uncertainty, stay ahead of emerging trends, and plan for a stable future.Exclusive BenefitsPlaybooksConcrete strategies, tactics, and solutions to real challenges from your peers and other experts. Published every 2 weeks. All Playbooks (Opens a new page)MasterclassesAgendaA weekly newsletter of timely insights that interpret today's business climate and help you chart a path to what's next. All Agenda (Opens a new page)LiveThe Strategy LabCustomer ServiceExecutive For Your TeamOther Subscriptions
GLP-1s and the High Cost of Providing Health Care
Rising demand for GLP-1 drugs like Ozempic and Wegovy is forcing companies to decide whether to cover, limit, or drop the benefit, with the medications costing employers up to $7,000 per employee annually. Prices are expected to fall once patents on the two dominant suppliers expire and generics enter the market, but until then companies must navigate the tradeoff between cost control and employee health and retention. Yale’s Robert Galvin outlines five strategies executives can use to manage the landscape in the short term.
96 words~1 min read
